InsiderTrades

Form 4 for ABUS Arbutus Biopharma Corp

Accepted 2026-09-23 20:31:52 ET · period of report 2026-09-18 · accession 0001447028-26-000052 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2026-09-23 20:31 2026-09-18 ABUS Nguyen Tuan CFO M - OptEx $3.57 +293.1K 366.6K +399% +$1.05M
D 2026-09-23 20:31 2026-09-18 ABUS Nguyen Tuan CFO F - Tax $5.07 -206.6K 160.0K -56% -$1.05M
DM 2026-09-23 20:31 2026-09-18 ABUS Nguyen Tuan CFO M - OptEx $0.00 -293.1K 160.9K -65% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Shares 2026-09-18 M A 265,625 $3.49 339,125 D — —
2 Common Common Shares 2026-09-18 M A 27,475 $4.39 366,600 D — —
3 Common Common Shares 2026-09-18 F D 206,637 $5.07 159,963 D — — (F1) The Reporting Person exercised options on September 18, 2026. The Issuer withheld an aggregate of 206,637 shares otherwise issuable upon the exercises to satisfy the aggregate exercise prices.
4 Derivative Stock Option (Right to Buy) 2026-09-18 M D 265,625 $0.00 484,375 D $3.49 · — to 2035-03-31 265,625 Common Shares (F2) The option, representing a right to purchase a total of 750,000 shares, vests over a four-year period, with 25% of the total shares subject to the option vesting on the 1st anniversary of the March 31, 2025 grant date and the remaining 75% vesting over the subsequent three-year period in substantially equal monthly installments at a rate of 1/48th of the total shares subject to the option each month, subject to the Reporting Person's continuous service as of each vesting date.
5 Derivative Stock Option (Right to Buy) 2026-09-18 M D 27,475 $0.00 160,925 D $4.39 · — to 2036-02-02 27,475 Common Shares (F3) The option, representing a right to purchase a total of 188,400 shares, vests over a four-year period, with 1/48th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the February 2, 2026 grant date, subject to the Reporting Person's continuous service as of each vesting date.